Edition:
United Kingdom

BB Biotech AG (BION.S)

BION.S on Swiss Exchange

66.30CHF
1:29pm GMT
Change (% chg)

CHF0.55 (+0.84%)
Prev Close
CHF65.75
Open
CHF65.75
Day's High
CHF66.60
Day's Low
CHF65.55
Volume
47,167
Avg. Vol
108,977
52-wk High
CHF68.25
52-wk Low
CHF52.05

Summary

Name Age Since Current Position

Erich Hunziker

63 2013 Chairman of the Board

Clive Meanwell

59 2011 Vice Chairman of the Board of Directors

Michael Hutter

2008 Chief Financial Officer, Chief Compliance Officer

Tanja Chicherio

2013 Marketing & Communication Officer

Silvia Schanz

2012 Director of Investor Relations

Maria-Grazia Iten-Alderuccio

2007 Director of Investor Relations

Claude Mikkelsen

2012 Director of Investor Relations

Jan Bootsma

Member of the Portfolio Management Team

Felicia Flanigan

2004 Member of the Investment Management Team

Nathalie Isidora-Kwidama

Member of the Portfolio Management Team

Christian Koch

2014 Member of the Investment Management Team

Daniel Koller

47 2010 Head Investment Management Team

Rudy Le Blanc

Member of the Portfolio Management Team

Stephen Taubenfeld

2013 Member of the Investment Management Team

Hugo van Neutegem

Member of the Portfolio Management Team

Dallas Webb

2006 Member of the Investment Management Team

Klaus Strein

2013 Member of the Board of Directors

Biographies

Name Description

Erich Hunziker

Dr. Erich Hunziker Ph.D., has been Chairman of the Board of BB Biotech Inc. since April 18, 2013. He is Chairman of the Audit Committee at the Company. He has served as Member of the Board of Directors of BB Biotech AG since March 21, 2011. He previously served as CFO of Roche from 2001 to 2010 with a seat on the Corporate Executive Committee and, from 2005 to 2010, as Deputy Head of the Corporate Executive Committee. From 1983 to 2001 he held various executive positions at Corange, Boehringer Mannheim and, before joining Roche, at Diethelm-Keller-Gruppe, where he ultimately served as CEO. He is Member of the Board of Directors of AB2Bio AG. Furthermore, he is Member of the Supervisory Board of the IMD Management School. He earned a Ph.D. in Industrial Engineering from Eidgenoessische Technische Hochschule Zuerich (the Swiss Federal Institute of Technology in Zurich) in 1983.

Clive Meanwell

Dr. Clive A. Meanwell, Ph.D., has been Vice Chairman of the Board of Directors at BB Biotech Inc. since 2011. Previously, he was Member of the Board of Directors from 2004. He is Member of the Audit Committee and Chairman of the Remuneration and Nomination Committee at the Company. He is Member of the Board of Directors and Chief Executive Officer of The Medicines Company, which he established in 1996. From 1995 to 1996 he was a founding partner and managing director of MPM Capital L.P., one of the world’s largest dedicated investors in life sciences. He previously held various positions at Hoffmann-La Roche in Basel and Palo Alto, California. His responsibilities included Worldwide Drug Regulatory Affair, clinical leader of product development as well as the launch of Roche/Amgen’s Neupogen. Dr. Meanwell received his M.D. and Ph.D. from the University of Birmingham in the UK where he also trained in medical oncology.

Michael Hutter

Mr. Michael Hutter has been Chief Financial Officer and Chief Compliance Officer at BB Biotech Inc. since 2008. He previously served as a senior auditing manager at PricewaterhouseCoopers for ten years. He is a Swiss chartered accountant and has a degree in Business Administration from the University of Applied Sciences( Hochschule fuer Wirtschaft Zuerich (HWZ) ) in Business Administration Zurich.

Tanja Chicherio

Ms. Tanja Chicherio has been Marketing & Communication Officer at BB Biotech Inc. since 2013. She joined the Marketing and Communication Team in 2007 and has headed the team since 2013. She previously worked for Ogilvy & Mather as a communications specialist for client advisory units. She earned a degree in media and communication sciences with a minor in Business Administration from the University of Zurich.

Silvia Schanz

Dr. Silvia Schanz has been Director of Investor Relations of BB Biotech Inc. since 2012. She holds a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology (ETH) Zurich and Master in Biochemistry, minor in Business Administration from the University Freiburg.

Maria-Grazia Iten-Alderuccio

Ms. Maria-Grazia Iten-Alderuccio has been Director of Investor Relations of BB Biotech Inc. since 2007. Her prior assignment was as Senior Relationship Manager with Citco Fund Advisors in Zurich, setting up and expanding their relationship management activities in Zurich. She holds Master’s degree in Linguistics from the University of Lausanne and Universita degli Studi di Firenze.

Claude Mikkelsen

Mr. Claude Mikkelsen has been Director of Investor Relations at BB Biotech Inc. since 2012. He holds Master’s degree in Economy and Law from Aalborg University, Denmark and also graduated from INSEAD, France.

Jan Bootsma

Mr. Jan Bootsma serves as Member of the Portfolio Management Team at BB Biotech Inc. Je joined the Company in 1995.

Felicia Flanigan

Ms. Felicia Flanigan has been Member of the Investment Management Team of BB Biotech Inc. since 2004. Before joining the team in 2004 she worked as a research analyst with Adams, Harkness & Hill. Previously she worked at SG Cowen in healthcare research. Ms. Flanigan holds a Master of Business Administration degree from the Suffolk University, Boston, and a Bachelor of Arts degree in Communications from the Boston College.

Nathalie Isidora-Kwidama

Ms. Nathalie Isidora-Kwidama is Member of the Portfolio Management Team of BB Biotech Inc. She has been working as investment manager for nearly 20 years. She joined the Company in 2007. She studied Modern Business Administration.

Christian Koch

Dr. Christian Koch has been Member of the Investment Management Team of BB Biotech Inc. since 2014. Prior to joining BB Biotech, he was a sell-side equity analyst in the Pharma & Biotech department of Bank am Bellevue. He has a Masters degree in Bioinformatics from Johann Wolfgang Goethe-Universitaet Frankfurt am Main and a Ph.D. degree in Cheminformatics & Computational Drug Design, which he completed at the Institute of Pharmaceutical Sciences of the Swiss Federal Institute of Technology in Zurich.

Daniel Koller

Dr. Daniel Koller has been Head Investment Management Team at BB Biotech Inc. since 2010. He joined the BB Biotech Investment Management Team in 2004. His area of specialty is cardiovascular diseases. Before joining the Company he spent four years in the financial sector, initially as an equity analyst at UBS Warburg and then as a private equity investor at equity4life. Dr. Koller gained Masters degree in biochemistry and Doctorate in Philosophy in biotechnology from Eidgenoessische Technische Hochschule Zuerich (ETH), Institute of Biotechnology of Federal Institute of Technology Zurich.

Rudy Le Blanc

Mr. Rudy Le Blanc is Member of the Portfolio Management Team at BB Biotech Inc. Since 2013 he has been Board Member and Managing Director of the BB Biotech branch office in Curacao. Prior to that he held various executive positions with the National Laboratory of Curacao and acted as operational director at a local Curacao private medical laboratory where he has been a Partner. He holds a degree in Medical Science from the Emory University in Atlanta.

Stephen Taubenfeld

Dr. Stephen Taubenfeld has been Member of the Investment Management Team of BB Biotech Inc. since 2013. He previously worked as an analyst at Iguana Healthcare Partners, of which he was a co-founder, and as a consultant for MerlinBioMed Group. He holds a M.D. and Ph.D. in Neuroscience, Brown University School of Medicine.

Hugo van Neutegem

Mr. Hugo van Neutegem is Member of the Portfolio Management Team at BB Biotech Inc. He has been Chairman of the BB Biotech branch office in Curacao since 2001. Prior to that he was the managing director of CITCO and had spent eight years with Ernst & Young in the Netherlands and the former Netherlands Antilles. He holds a degree in Tax Law from the Universiteit Leiden in the Netherlands.

Dallas Webb

Mr. Dallas J. Webb has been Member of the Investment Management Team of BB Biotech Inc. since 2006. He previously worked for Sterling Financial Investment Group and Stanford Group. His first assignment as a biotech analyst was with Adams, Harkness & Hill. Mr. Webb holds a Master of Business Administration degree from the Texas Christian University. He also gained Bachelor of Science degree in microbiology and zoology from Louisiana State University.

Klaus Strein

Prof. Dr. Klaus Strein, M.D., Ph.D., has been Member of the Board of Directors at BB Biotech Inc. since April 18, 2013. He is Member of the Nomination and Remuneration Committee at the Company. He was with Roche from 1998 to 2011, during which time he held various responsibilities, including head of pharma research activities in Germany, head of global research activities for therapeutic proteins/monoclonal antibodies, of research and early development activities for low and high molecular weight active ingredients, and of global pharma research. From 1979 to 1998 he served in various positions at Boehringer Mannheim. He holds post-graduate degrees in chemistry and medicine from the University of Heidelberg, where he was also appointed Adjunct Professor. He is also a Member of the Board of Directors of NovImmune SA.